Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0004057,
umls-concept:C0005821,
umls-concept:C0014792,
umls-concept:C0030705,
umls-concept:C0033414,
umls-concept:C0042373,
umls-concept:C0302350,
umls-concept:C0439092,
umls-concept:C0547047,
umls-concept:C0678226,
umls-concept:C0695347,
umls-concept:C1280500,
umls-concept:C1280519,
umls-concept:C2698651
|
| pubmed:issue |
4
|
| pubmed:dateCreated |
1998-3-6
|
| pubmed:abstractText |
Aspirin (acetylsalicylic acid, ASA) is widely used for secondary prevention of ischemic vascular events, although its protection only occurs in 25% of patients. We previously demonstrated that platelet reactivity is enhanced by a prothrombotic effect of erythrocytes in a thromboxane-independent manner. This diminishes the antithrombotic therapeutic potential of ASA. Recent data from our laboratory indicate that the prothrombotic effect of erythrocytes also contains an ASA-sensitive component. In accordance with this observation, intermittent treatment with high-dose ASA reduced the prothrombotic effects of erythrocytes ex vivo in healthy volunteers. In the present study, the effects of platelet-erythrocyte interactions were evaluated ex vivo in 82 patients with vascular disease: 62 patients with ischemic heart disease treated with 200 mg ASA/d and 20 patients with ischemic stroke treated with 300 mg ASA/d.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0009-7322
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
3
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
350-5
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:9468208-Adult,
pubmed-meshheading:9468208-Aged,
pubmed-meshheading:9468208-Aged, 80 and over,
pubmed-meshheading:9468208-Aspirin,
pubmed-meshheading:9468208-Blood Platelets,
pubmed-meshheading:9468208-Brain Ischemia,
pubmed-meshheading:9468208-Cerebrovascular Disorders,
pubmed-meshheading:9468208-Dose-Response Relationship, Drug,
pubmed-meshheading:9468208-Erythrocytes,
pubmed-meshheading:9468208-Female,
pubmed-meshheading:9468208-Fibrinolytic Agents,
pubmed-meshheading:9468208-Humans,
pubmed-meshheading:9468208-Male,
pubmed-meshheading:9468208-Middle Aged,
pubmed-meshheading:9468208-Myocardial Ischemia,
pubmed-meshheading:9468208-Platelet Aggregation Inhibitors,
pubmed-meshheading:9468208-Serotonin,
pubmed-meshheading:9468208-Vascular Diseases
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity.
|
| pubmed:affiliation |
Research Center, University Hospital La Fe, Valencia, Spain. mteresas@san.gva.es
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|